Search Results
Your search for The ASCO ,The ASCO matches 21400 pages
Showing 13401 - 13450AUA 2017: Studies Examine Bladder Cancer Risk and Mortality in E-Cigarette and Traditional Smokers
Data presented at the 2017 Annual Scientific Meeting of the American Urological Association (AUA) showed harmful links between the use of e-cigarettes and bladder cancer risk, and associated the smoking of traditional cigarettes to a higher risk of mortality among patients with bladder cancer. Even ...
AUA 2017: Association of Oncotype DX Genomic Prostate Score Test With Prostate Cancer–Specific Death and Metastases in Early-Stage Disease
New results presented at the 2017 American Urological Association (AUA) Annual Meeting from a large, community-based, multicenter clinical validation study conducted at Kaiser Permanente confirmed that the Oncotype DX Genomic Prostate Score (GPS) test is a strong independent predictor of prostate...
AUA 2017: New Studies Demonstrate Impact of BRCA, DNA Repair Gene Mutations in Prostate Cancer
Data presented at the 2017 Annual Scientific Meeting of the American Urological Association (AUA) showed new findings related to the impact of certain genetic mutations on the risk and development of prostate cancer, in particular metastatic disease. Male BRCA Mutations An analysis by Mano et al...
ASCO 2017: Chance of Colon Cancer Recurrence Nearly Cut in Half in Patients Who Consume Nuts
An observational study of 826 patients with stage III colon cancer showed that those who consumed 2 ounces or more of nuts per week had a 42% lower chance of cancer recurrence and 57% lower chance of death than those who did not eat nuts. A secondary analysis revealed the benefit of nut consumption ...
ASCO 2017: HPV Vaccination May Reduce Oral HPV Infections but Is Still Underutilized
In one of the first large studies to explore the possible impact of human papillomavirus (HPV) vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was...
ASCO 2017: Gefitinib Treatment Can Delay Recurrence of Intermediate-Stage Lung Cancer
The targeted therapy gefitinib (Iressa) appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II to IIIA non–small cell lung cancer ...
ASCO 2017: Healthy Lifestyle After Colon Cancer Diagnosis Helps Extend Survival
A study of 992 patients with stage III colon cancer found that those who reported a healthy lifestyle during and following adjuvant treatment had a 42% lower chance of death and a trend for lower chance of cancer recurrence than those who had less healthy lifestyles. The study will be presented by...
ASCO 2017: Increase in Early-Stage Cancer Diagnoses After Implementation of the Affordable Care Act
An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1% increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage. Considering the thousands of people diagnosed with these cancers annually, a 1% increase in...
ASCO 2017: Adjuvant Capecitabine May Extend Survival in Biliary Tract Cancer
A phase III randomized clinical trial in 447 patients with biliary tract cancers showed that treating the disease with capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. The finding could provide the basis for a new standard of care in the disease. This ...
First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy
After phase I results of Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) trial, published by Gardner et al in Blood, showed T-cell immunotherapy to be effective in sending 93% of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into complete initial...
New Canadian Guideline Provides Advice to Physicians to Avoid Overprescribing of Opioids
Opioid overdoses are claiming the lives of thousands of Canadians. The impact of the opioid crisis continues to be devastating to individuals, families, and communities. Inappropriate prescribing of opioids has led to long-term dependence on this class of drugs. To help address problematic...
Hypofractionated Radiotherapy vs Conventionally Fractionated Radiotherapy in Early-Stage Glottic Cancer
Radiotherapy alone is often used to treat early-stage glottic cancer. However, the optimal radiation treatment schedule remains unknown. Both hypofractionated radiotherapy and conventionally fractionated radiotherapy are recommended treatment options. In an attempt to compare differences in overall ...
Delaying Colonoscopy for 9 Months or More After Positive Fecal Screening Test May Increase Risk of Colorectal Cancer
The risk of colorectal cancer increased significantly when colonoscopy was delayed by more than 9 months following a positive fecal screening test, according to a large Kaiser Permanente study published by Rutter et al in the Journal of the American Medical Association. “With this study, we...
Changes in HER2 Breast Cancer Testing According to 2007 and 2013 ASCO/CAP Guidelines
Hanna et al have reported that the 2013 update to the 2007 ASCO/College of American Pathologists (CAP) recommendations for HER2 testing in breast cancer did not result in changes in the overall HER2-positivity rate but was associated with a higher rate of equivocal results. Their findings were...
ASCO Remembers Robert L. Comis, MD, FASCO
ASCO and the oncology community are deeply saddened by the loss of Robert L. Comis, MD, FASCO, who passed away on May 10, 2017, at the age of 71. Dr. Comis was a powerful voice in support of clinical trials, cooperative group research, and patient advocacy throughout his career. “Bob helped...
FDA Approves Ribociclib/Letrozole Co‑Pack for Postmenopausal Patients With Advanced or Metastatic Breast Cancer
On May 8, the U.S. Food and Drug Administration (FDA) approved the copackaging of ribociclib (Kisqali) and letrozole (Femara) tablets for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal ...
FDA Approves Pembrolizumab as First-Line Combination Therapy With Pemetrexed and Carboplatin for Metastatic Nonsquamous NSCLC
On May 10, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, in combination with pemetrexed (Alimta) and carboplatin for the first-line treatment of metastatic nonsquamous non–small cell lung cancer...
ONS 2017: Hospital-Wide Initiative to Standardize the Administration of Vinca Alkaloids Using a Mini-Bag, Side-Arm Technique
Many patients with cancer who receive vinca alkaloids such as vincristine have a treatment regimen including other chemotherapy drugs that are administered intrathecally. If vincristine is mistakenly administered into the spinal fluid, it is uniformly fatal, causing ascending paralysis, neurologic...
ASCO-NCI Collaboration Finds Widespread Benefits of Centralizing Coverage Analyses for Multisite Clinical Trials
ASCO has released findings from a collaboration with the National Cancer Institute (NCI) that explored centralizing the development of coverage analyses for multisite cancer clinical trials. In an ASCO special article published by Szczepanek et al in the Journal of Oncology Practice,...
ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer
Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference (Abstract OC-0426). Previous research has suggested that radiotherapy may be of little help to...
ESTRO 2017: HDR Brachytherapy in Prostate Cancer Does Not Cause Higher Toxicity, Results in High Patient Satisfaction
Treating prostate cancer with a single, high dose of radiation delivered precisely to the site of the tumor results in good quality of life and fewer trips to the hospital, with adverse side effects that are no worse than if the radiation treatment had been given in several lower doses. These...
ESTRO 2017: ESTRO Announces GIRO, a Project to Save 1 Million Lives in Under 20 Years
Although radiation therapy is an essential part of modern cancer treatment, and is indicated for about half of all new cancer patients, facilities for its provision are sadly lacking in many countries worldwide. Indeed, 29 out of 52 African nations have no radiotherapy facilities whatsoever. At the ...
ESTRO 2017: Cervical Cancer Survivors Frequently Suffer From Long-Term Fatigue, Insomnia, and Hot Flashes
Around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue, or hot flashes at some point, according to new research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference (Abstract OC-0051). Cervical...
FDA Grants Accelerated Approval to Avelumab for Urothelial Carcinoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (Bavencio) for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant...
Luis A. Diaz, MD, Named Head of Solid Tumor Oncology at MSK
Luis A. Diaz, MD, has been named Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Dr. Diaz most recently served as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Diaz formally...
A New Book Deals With an Age-Old Crisis: Cancer Patients and Mortality
The field of psycho-oncology began to take hold in the mid-1970s, when the “C” word was beginning to lose its long-held stigmatization, and patients with cancer could finally begin to openly reveal their diagnosis and express their feelings about their life-threatening disease. Despite that social ...
ELCC 2017: Prospective Study Shows Concordance of EGFR Mutation Detection Between ctDNA and Tumor Samples
Detection of EGFR mutations in circulating tumor (ct) DNA from plasma samples can be accomplished using the cobas platform, according to findings presented by Kumar et al at the 2017 European Lung Cancer Conference (ELCC) (Abstract 95PD). Assays of ctDNA offer a noninvasive method of finding EGFR...
Ahmad Samer Al-Homsi, MD, MBA, to Lead New Bone Marrow Transplantation Initiative at NYU
Hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead a new bone marrow transplantation program at New York University (NYU) Langone’s Perlmutter Cancer Center for treating blood-borne cancers and potentially utilize transplantation as an adjunct to immunotherapy for solid tumors. He...
ELCC 2017: Specific Immune Cell Profiles Potentially Identify Patients With Lung Cancer Responsive to Anti–PD-1 Immunotherapy
An investigation of immune cell subtypes in the tumor microenvironment of patients with lung adenocarcinoma and squamous cell carcinoma (SCC) identified an immune subgroup that associates with prolonged patient survival and may be prognostic of response to nivolumab, according to findings presented ...
Leukemia & Lymphoma Society Launches ‘Myeloma Link’ in Collaboration With National Black Church Initiative
The Leukemia & Lymphoma Society (LLS) together with the National Black Church Initiative (NBCI) announced the launch of a church-based initiative addressing striking health-care disparities among African Americans with multiple myeloma. Black Americans have twice the incidence of multiple...
ELCC 2017: Ensartinib Demonstrates CNS Activity in ALK-Positive NSCLC
Ensartinib demonstrated intracranial responses in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, according to findings presented by Reckamp et al at the 2017 European Lung Cancer Conference (ELCC)...
ASCO Answers Palliative Care: A Resource for Patients
The ASCO Answers Palliative Care booklet shows how palliative care is used to manage symptoms and side effects; help with practical concerns; address spiritual questions; and support caregivers, family, and friends. Readers will find: Practical advice on how to access palliative care services...
Register Today for the ASCO Research Community Forum 2017 Annual Meeting
Registration is now open for the ASCO Research Community Forum 2017 Annual Meeting. Join fellow physician investigators and research staff from across the country for this unique meeting focused on sharing best practices for effectively conducting and managing clinical research and developing...
ASCO Selects 2017–2018 Health Policy Fellows
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its 2nd year. The fellowship provides early-career oncologists the skills they need to monitor and shape the regulatory and legislative ...
Social Media: A Knowledge-Sharing Tool in Oncology
Social media is a uniquely positioned platform that can spread specific knowledge to a larger audience. Unlike traditional media, it allows anyone to join the conversation, and according to the Pew Research Center, it is here to stay, with 79% of online American adults using Facebook and 24% using...
QOPI® Certification Program Certifies First Practice in Brazil
On April 5, ASCO announced that Instituto de Oncologia do Vale (IOV) was the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). IOV is the second international practice to achieve this milestone in...
Support the Conquer Cancer Foundation at the 2017 ASCO Annual Meeting
Lace Up to Conquer Cancer The ASCO Annual Meeting involves a lot of walking—wear comfortable shoes and show your support for cancer research by participating in the Conquer Cancer Foundation (CCF) Laces campaign. Make a donation to CCF when you register for the 2017 Annual Meeting, and you will...
ELCC 2017: Development and Validation of Lung Toxicity Prediction Models Aids Effective Use of Radiotherapy in NSCLC
Validation using patient data of an outcome prediction model for the development of dyspnea subsequent to radiotherapy revealed that the prognostic factors in the model did not adequately predict for delta toxicity endpoints, according to results reported by Defraene et al at the 2017 European Lung ...
Donor Spotlight: Conquering Cancer With Kelly Cares Foundation
Kelly Cares Foundation recently became one of the newest supporters of the Conquer Cancer Foundation of ASCO Young Investigator Awards, the flagship program begun in 1984 to support early-career cancer researchers. The mission of Kelly Cares Foundation is to inspire hope by investing resources to...
Cancer Research UK Awards Six U.S. Scientists $87 Million as Part of ‘Grand Challenge’
Cancer Research UK has announced that six leading American scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research. The initial $87 million “Grand Challenge” fund will be distributed across 4 international teams of academics from 6...
Neoadjuvant Immunotherapy in High-Risk Melanoma: A New Approach
Melanoma is an immunogenic tumor, as it expresses various melanoma-specific antigens. However, it is both biologically and clinically heterogeneous. Biologically, it expresses different melanoma antigens and has diverse genetic profiles among different patients. Clinically, it varies in the amount ...
Karmanos Cancer Institute Now Offers Image-Fusion Technology to Detect Prostate Cancer
The Barbara Ann Karmanos Cancer Institute is using a sophisticated new way to diagnose and treat prostate cancer more effectively. Urology specialists at Karmanos have begun using the UroNav Fusion Biopsy System, which fuses three-dimensional MRI (magnetic resonance imaging) images of the prostate...
Nivolumab/Ipilimumab Combination Improves Survival Over Ipilimumab Alone in Patients With Melanoma
The race is on to identify combinations of immune checkpoint inhibitors that can improve outcomes over the use of immune checkpoint inhibitor monotherapy. Updated results of the phase III CheckMate 067 trial found the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved survival in...
On the Variance of Cancer Outcomes by Time and Geography
A recent study by Mokdad and colleagues, reviewed in this issue of The ASCO Post, looks at cancer demographic data for 28 cancers and compares mortality rates in 1980 to results in 2014.1 Publishing mortality rates by geographic area and the observation of significant differences is not new. The...
ELCC 2017: Study Shows White Blood Cell–Boosting Drugs Safe During Small Cell Lung Cancer Chemoradiotherapy
A late-breaking subanalysis of the phase III CONVERT trial presented by Gomes et al at the 2017 European Lung Cancer Conference (ELCC) shows that white blood cell–boosting drugs are safe during concurrent chemoradiotherapy of small cell lung cancer (SCLC, Abstract LBA2_PR). “The...
ELCC 2017: Some Patients With Lung Cancer Benefit From Immunotherapy Even After Disease Progression
Some patients with advanced lung cancer benefit from immunotherapy, even after the disease has progressed as evaluated by standard criteria, according to research presented by Artal-Cortes et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 96PD). The findings pave the way for certain ...
ELCC 2017: White Blood Cell Count May Predict Response to Lung Cancer Immunotherapy
White blood cell counts may predict whether patients with lung cancer will benefit from immunotherapy, according to research presented by Tiseo et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 30PD). “Immune checkpoint inhibitors such as nivolumab [Opdivo] and...
ELCC 2017: Osimertinib Improves Symptoms in Advanced Lung Cancer
Osimertinib (Tagrisso) improved cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented by Lee et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 85O). “With my...
IMPAKT 2017: Few Variations in Somatic Mutations Observed Between Pregnant and Nonpregnant Patients With Breast Cancer
Findings comparing the mutational landscape in pregnant and nonpregnant patients with breast cancer that sought to define whether the disease may have a different biology in pregnant women were reported by Loibl et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract...
IMPAKT 2017: Luminal Androgen Receptor Subtype of Triple-Negative Breast Cancer Demonstrates Sensitivity to CDK4/6 Inhibition
Researchers have identified a subtype of triple-negative breast cancer that may be responsive to inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), according to findings presented by Asghar et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract 44P). This study also...
